PRTC

PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group

Data presented at the CHEST 2025 Annual Meeting highlight deupirfenidone's differentiated profile and potential to address unmet needs across age groups PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))